生物可吸收支架与钴铬合金依维莫司洗脱支架治疗冠心病的Meta分析
2016-04-06庞思潘道蓉朱灏吴文蔡金赞冒晨昱张瑶俊
庞思,潘道蓉,朱灏,吴文,蔡金赞,冒晨昱,张瑶俊
生物可吸收支架与钴铬合金依维莫司洗脱支架治疗冠心病的Meta分析
庞思,潘道蓉*,朱灏,吴文,蔡金赞,冒晨昱,张瑶俊
摘要
关键词冠状动脉疾病;支架;随机对照试验;Meta分析
作者单位:210006 江苏省南京市,东南大学附属中大医院 心血管内科 东南大学医学院心血管病研究所(庞思、冒晨昱);南京医科大学南京市第一医院 心血管内科(潘道蓉、朱灏、吴文、蔡金赞、张瑶俊)
Meta-analysis of Absorb Bioresorbable Vascular Scaffold Versus Cobalt Chromium-everolimus Eluting Stent for Treating the Patients With Coronary Artery Disease
PANG Si, PAN Dao-rong, ZHU Hao, WU Wen, CAI Jin-zan, MAO Chen-yu, ZHANG Yao-jun.
Department of Cardiology, Zhongda Hospital, Medical School of Southeast University, Nanjing (210006), Jiangsu, China Corresponding Author: ZHANG Yao-jun, Email: 13770668667@139.com
Abstract
Objective: To systemically review the safety and efficacy of Absorb bioresorbable vascular scaffold (Absorb BVS) versus cobalt chromium-everolimus eluting stent (CoCr-EES) for treating the patients with coronary artery disease (CAD) by percutaneous coronary intervention (PCI).
Methods: We searched relevant literatures in PubMed, Embase, Cochrane Library, CNKI and Wanfang database from 2008-01 to 2015-10, meanwhile, collected published data and randomized controlled trials from meeting abstracts and websites to compare Absorb BVS and CoCr-EES for treating CAD patients. The quality of literatures were assessed and extracted by modified Jadad score, Meta-analysis was conducted by STATA 12.0 soft ware.
Results: There were 4 eligible trials with 3,389 patients were enrolled. Absorb BVS group, n=2,164 and CoCr-EES group, n=1,225. During the mean of 1.1 years follow-up period, the following incidences were similar between 2 groups: target lesion failure (OR=1.29, 95% CI 0.95-1.74, P=0.10), all cause death (OR=1.31, 95% CI 0.60-2.87, P=0.50), cardiac death (OR=1.38, 95% CI 0.45-4.24, P=0.57), myocardial infarction (OR=1.30, 95% CI 0.93-1.80, P=0.12), definite or probable stent thrombosis (OR=2.08, 95% CI 0.95-4.54, P=0.07), re-vascularization (OR=1.03, 95% CI 0.80-1.33, P=0.81), target lesion re-vascularization (OR=1.06, 95% CI 0.67-1.66, P=0.81) and the patient-oriented composite endpoint (OR=0.95, 95% CI 0.66-1.35, P=0.76).
Conclusion: Absorb BVS and CoCr-EES had the similar safety and efficacy for treating the low and moderate risk CAD patients who had angina, ischemia while without symptoms. The longer period of follow-up study and larger randomized, controlled clinical trials were needed for Absorb BVS application in clinical practice.
Key words Coronary artery disease; Stent; Randomized controlled trials; Meta-analysis
(Chinese Circulation Journal, 2016,31:15.)
在经皮冠状动脉介入治疗(PCI)领域,球囊血管成形术、裸金属支架及药物洗脱支架(DES)的应用逐渐提高了冠心病介入疗效,尤其是随着新一代DES应用于临床,支架内血栓事件明显减少。然而,冠状动脉(冠脉)内金属支架的长期存留,仍然无法完全克服晚期、极晚期支架内血栓及再狭窄等问题[1]。
近年来,生物可吸收支架(BVS)以其独特的技术优势和良好的临床应用前景被誉为介入心脏病学的第4次变革[2, 3]。以Absorb BVS(雅培公司,美国)为代表的BVS,能够在1年内提供与金属支架相媲美的支撑作用,同时其携载的抗增殖药物也能有效抑制新生内膜增生,最终支架骨架能在人体内完全降解,达到远期无残留的“理想状态”[4]。Absorb BVS以聚左旋乳酸为骨架,通过外消旋聚乳酸涂层洗脱抗增殖药物依维莫司。早期的注册研究已初步证实了Absorb BVS在治疗简单冠脉病变的可行性[5, 6]。而该支架对比现今临床公认的钴铬合金依维莫司洗脱支架(cobalt chromium-everolimus eluting stents, CoCr-EES)的随机对照系列研究,旨在进一步评估其治疗中、低危冠心病患者的安全性和有效性。……
